Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases

Author:

Berger Nathan A1,Besson Valerie C2,Boulares A Hamid3,Bürkle Alexander4,Chiarugi Alberto5,Clark Robert S6,Curtin Nicola J7,Cuzzocrea Salvatore8,Dawson Ted M9,Dawson Valina L10,Haskó György11,Liaudet Lucas12,Moroni Flavio13,Pacher Pál14,Radermacher Peter15,Salzman Andrew L16,Snyder Solomon H17,Soriano Francisco Garcia18,Strosznajder Robert P19,Sümegi Balázs20,Swanson Raymond A21,Szabo Csaba22ORCID

Affiliation:

1. Center for Science, Health and Society; Case Western Reserve University School of Medicine; Cleveland OH USA

2. EA4475 - Pharmacologie de la Circulation Cérébrale, Faculté de Pharmacie de Paris; Université Paris Descartes, Sorbonne Paris Cité; Paris France

3. The Stanley Scott Cancer Center, School of Medicine; Louisiana State University Health Sciences Center; New Orleans LA USA

4. Molecular Toxicology Group, Department of Biology; University of Konstanz; Constance Germany

5. Department of Health Sciences, Section of Clinical Pharmacology and Oncology, Headache Center - University Hospital; University of Florence; Florence Italy

6. Department of Critical Care Medicine and Safar Center for Resuscitation Research; University of Pittsburgh; Pittsburgh PA USA

7. Newcastle University, Northern Institute for Cancer Research, Medical School; University of Newcastle Upon Tyne; Newcastle Upon Tyne UK

8. Department of Pharmacology; University of Messina; Messina Italy

9. Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering and Department of Neurology and Department of Pharmacology and Molecular Sciences and Solomon H. Snyder Department of Neuroscience; Johns Hopkins University School of Medicine; Baltimore MD USA

10. Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering and Department of Neurology and Department of Physiology and Solomon H. Snyder Department of Neuroscience; Johns Hopkins University School of Medicine; Baltimore MD USA

11. Department of Surgery and Center for Immunity and Inflammation; Rutgers-New Jersey Medical School; Newark NJ USA

12. Department of Intensive Care Medicine and Burn Center; University Hospital Medical Center, Faculty of Biology and Medicine; Lausanne Switzerland

13. Department of Neuroscience; Università degli Studi di Firenze; Florence Italy

14. Laboratory of Physiologic Studies, Section on Oxidative Stress Tissue Injury; NIAAA, NIH; Bethesda USA

15. Institute of Anesthesiological Pathophysiology and Process Engineering; University Hospital; Ulm Germany

16. Radikal Therapeutics Inc.; West Tisbury MA USA

17. Department of Neurology and Solomon H. Snyder Department of Neuroscience; Johns Hopkins University School of Medicine; Baltimore MD USA

18. Departamento de Clínica Médica; Faculdade de Medicina da Universidade de São Paulo; São Paulo SP Brazil

19. Laboratory of Preclinical Research and Environmental Agents, Department of Neurosurgery, Mossakowski Medical Research Centre; Polish Academy of Sciences; Warsaw Poland

20. Department of Biochemistry and Medical Chemistry; University of Pécs; Pécs Hungary

21. Department of Neurology; University of California San Francisco and San Francisco Veterans Affairs Medical Center; San Francisco CA USA

22. Department of Anesthesiology; University of Texas Medical Branch; Galveston TX USA

Funder

National Institutes of Health

Publisher

Wiley

Subject

Pharmacology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3